Compare NNNN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | AUPH |
|---|---|---|
| Founded | 2021 | 1993 |
| Country | Germany | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | NNNN | AUPH |
|---|---|---|
| Price | $21.75 | $13.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 29.0K | ★ 937.4K |
| Earning Date | 04-28-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $16.53 |
| Revenue Next Year | N/A | $16.24 |
| P/E Ratio | $446.57 | ★ $6.78 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $5.91 | $6.83 |
| 52 Week High | $55.65 | $16.54 |
| Indicator | NNNN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 43.02 |
| Support Level | $19.53 | $13.52 |
| Resistance Level | $30.70 | $15.23 |
| Average True Range (ATR) | 1.81 | 0.44 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 37.28 | 8.06 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.